
|Articles|September 1, 2003
Using bisphosphonates to treat PCa-related bone events
Author(s)E. David Crawford, MD, Shandra Wilson, MD
Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to Enolen for localized prostate cancer
2
Trial to assess testosterone undecanoate in older men with hypogonadism
3
Pivotal trial of Butterfly Device for BPH reaches final completion
4
Genomic classifier score linked with focal therapy outcomes in prostate cancer
5




















